-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (600276.SH) Subsidiary HRS-7535 Tablet Marketing License Application Accepted

Zhitongcaijing·09/02/2026 08:57:04
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's application for a drug marketing license for HRS-7535 tablets was accepted by the State Drug Administration. Proposed Indications (or Functional Indications): Used for blood sugar control in adult type 2 diabetics.